PET/CT Imaging and Histological Data for 23 Neuroendocrine Neoplasm Patients

23 patients with aggressive neuroendocrine neoplasms underwent dual-tracer PET/CT scans and biopsies. The study measured PET parameters and immunohistochemical FAP expression to correlate with progression-free survival. FDG+/FAPI- lesions were found in 9 patients and were associated with significantly shorter survival.

Use Cases

• Predicting progression-free survival based on PET/CT imaging metrics like SUVmax and tumor volume.
• Correlating histological FAP expression scores with imaging-derived tumor volume and total lesion uptake.
• Identifying discordant FDG+/FAPI- lesions as a prognostic factor for patient risk stratification.
• Comparing the prognostic value of dual-tracer PET/CT imaging versus single-lesion biopsy for aggressive NENs.

Strengths

• Includes data from 23 patients with aggressive neuroendocrine neoplasms.
• Correlates multiple PET parameters (SUVmax, SUVmean, SUVpeak, TV, TLU) with histological FAP expression.
• Identifies a specific prognostic factor (FDG+/FAPI- lesions) associated with a hazard ratio of 3.383.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is 65.2 KB, indicating a very limited scope and sample size.

Provenance

Source

Tim Jedamzik

Collection Method

Data likely collected from clinical PET/CT scans and biopsies of 23 patients.

Freshness

Last updated 2026-04-10 06:03:28; freshness should be verified.